UroGen Historical Financial Ratios
| URGN Stock | USD 12.70 0.04 0.32% |
UroGen Pharma is promptly reporting on over 98 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Price To Sales Ratio of 4.97, Dividend Yield of 0.0, Days Sales Outstanding of 98.77 or Invested Capital of 0.0 will help investors to properly organize and evaluate UroGen Pharma financial condition quickly.
UroGen |
About UroGen Financial Ratios Analysis
UroGen PharmaFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate UroGen Pharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on UroGen financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across UroGen Pharma history.
UroGen Pharma Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing UroGen Pharma stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on UroGen Pharma sales, a figure that is much harder to manipulate than other UroGen Pharma multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most ratios from UroGen Pharma's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into UroGen Pharma current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.At this time, UroGen Pharma's Graham Number is very stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 0.89 | 1.38 | 1.44 | 1.51 | Days Of Inventory On Hand | 342.0 | 206.25 | 221.2 | 210.14 |
UroGen Pharma fundamentals Correlations
Click cells to compare fundamentals
UroGen Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
UroGen Pharma fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 38.1K | 33.26 | 4.42 | 3.14 | 5.23 | 4.97 | |
| Ptb Ratio | 3.8 | 4.07 | 25.26 | (2.28) | (6.63) | (6.3) | |
| Book Value Per Share | 8.78 | 4.42 | 0.38 | (3.89) | (2.26) | (2.15) | |
| Free Cash Flow Yield | (0.1) | (0.27) | (0.4) | (0.43) | (0.18) | (0.19) | |
| Operating Cash Flow Per Share | (3.46) | (4.86) | (3.8) | (3.84) | (2.65) | (2.78) | |
| Stock Based Compensation To Revenue | 0.77 | 27.16 | 1.7K | 2.38 | 0.48 | 0.16 | |
| Capex To Depreciation | 1.34 | 0.25 | 0.59 | 0.42 | 0.14 | 0.11 | |
| Pb Ratio | 3.8 | 4.07 | 25.26 | (2.28) | (6.63) | (6.3) | |
| Ev To Sales | 35.4K | 24.58 | 3.51 | 3.82 | 5.29 | 5.03 | |
| Free Cash Flow Per Share | (3.48) | (4.92) | (3.83) | (3.85) | (2.66) | (2.79) | |
| Roic | (0.58) | (1.35) | (11.12) | (9.08) | (2.04) | (2.15) | |
| Net Income Per Share | (4.9) | (5.9) | (4.96) | (4.79) | (3.55) | (3.72) | |
| Research And Ddevelopement To Revenue | 2.7K | 4.01 | 0.99 | 0.82 | 0.55 | 0.52 | |
| Capex To Revenue | 18.06 | 0.1 | 0.0157 | 0.003947 | 0.002345 | 0.002228 | |
| Cash Per Share | 7.16 | 7.03 | 3.99 | 4.38 | 4.75 | 3.93 | |
| Pocfratio | (9.65) | (3.71) | (2.5) | (2.31) | (5.66) | (5.95) | |
| Capex To Operating Cash Flow | (0.004576) | (0.0115) | (0.008858) | (0.002901) | (0.00254) | (0.002413) | |
| Pfcf Ratio | (9.6) | (3.66) | (2.48) | (2.3) | (5.65) | (5.93) | |
| Income Quality | 0.49 | 0.68 | 0.82 | 0.8 | 0.75 | 0.78 | |
| Roe | (0.56) | (1.33) | (13.17) | 1.23 | 1.57 | 1.65 | |
| Ev To Operating Cash Flow | (8.98) | (2.74) | (1.99) | (2.81) | (5.73) | (6.02) | |
| Pe Ratio | (6.81) | (3.05) | (1.92) | (1.85) | (4.23) | (4.44) | |
| Ev To Free Cash Flow | (8.94) | (2.71) | (1.97) | (2.8) | (5.72) | (6.0) | |
| Earnings Yield | (0.15) | (0.33) | (0.52) | (0.54) | (0.24) | (0.25) | |
| Net Debt To E B I T D A | 0.44 | 0.83 | 0.49 | (0.56) | (0.0817) | (0.0857) | |
| Current Ratio | 7.59 | 7.63 | 5.39 | 5.11 | 5.42 | 7.4 | |
| Tangible Book Value Per Share | 8.78 | 4.42 | 0.38 | (3.89) | (2.26) | (2.15) | |
| Graham Number | 31.11 | 24.23 | 6.48 | 20.47 | 13.43 | 13.49 | |
| Shareholders Equity Per Share | 8.78 | 4.42 | 0.38 | (3.89) | (2.26) | (2.15) | |
| Capex Per Share | 0.0158 | 0.0558 | 0.0337 | 0.0111 | 0.006728 | 0.006392 | |
| Graham Net Net | 6.09 | 6.14 | (0.49) | (4.97) | (3.2) | (3.04) |
Pair Trading with UroGen Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if UroGen Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UroGen Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against UroGen Stock
| 0.71 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.7 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.68 | BHC | Bausch Health Companies | PairCorr |
| 0.67 | GILD | Gilead Sciences | PairCorr |
| 0.56 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
The ability to find closely correlated positions to UroGen Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace UroGen Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back UroGen Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling UroGen Pharma to buy it.
The correlation of UroGen Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as UroGen Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if UroGen Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for UroGen Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share 2.389 | Quarterly Revenue Growth 0.209 | Return On Assets (0.21) | Return On Equity (14.81) |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.